A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication previously approved for adults—can safely and effectively improve the flow of blood through compromised left ventricles in youth with hypertrophic cardiomyopathy (HCM). Published in the New England Journal of Medicine, the study is the first phase 3 randomized, double-blind, placebo-controlled trial conducted in youth with HCM, the most common inherited type of heart disease.
This article was originally published on MedicalXpress.com
